SIRP-alpha mAb program (Arch Oncology)

N/A

Report date: 2025/03/20 09:22:45

Base Information

Drug NameSIRP-alpha mAb program (Arch Oncology)
Drug Alias NameSIRPa checkpoint inhibitor (Arch Oncology)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionSignal-regulatory protein alpha inhibitors
TargetsSignal-regulatory protein alpha
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesArch Oncology Inc
China Registration ClassN/A

Develop Information

Active CompaniesArch Oncology Inc
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A